These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 8445426)

  • 1. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
    Bär BM; Schattenberg A; Mensink EJ; Geurts Van Kessel A; Smetsers TF; Knops GH; Linders EH; De Witte T
    J Clin Oncol; 1993 Mar; 11(3):513-9. PubMed ID: 8445426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation.
    Santini V; Zoccolante A; Bosi A; Guidi S; Saccardi R; Vannucchi AM; Martinazzo G; Bernabei PA; Ferrini PR
    Haematologica; 1996; 81(3):201-7. PubMed ID: 8767524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
    Baurmann H; Nagel S; Binder T; Neubauer A; Siegert W; Huhn D
    Blood; 1998 Nov; 92(10):3582-90. PubMed ID: 9808551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of graft-versus-host disease on the eradication of minimal residual leukemia detected by polymerase chain reaction in chronic myeloid leukemia patients after bone marrow transplantation.
    Arnold R; Janssen JW; Heinze B; Bunjes D; Hertenstein B; Wiesneth M; Kubanek B; Heimpel H; Bartram CR
    Leukemia; 1993 May; 7(5):747-51. PubMed ID: 8483329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Red blood cell phenotyping is a sensitive technique for monitoring chronic myeloid leukaemia patients after T-cell-depleted bone marrow transplantation and after donor leucocyte infusion.
    Schaap N; Schattenberg A; Bär B; Mensink E; de Man A; Geurts van Kessel A; de Witte T
    Br J Haematol; 2000 Jan; 108(1):116-25. PubMed ID: 10651734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Mackinnon S; Barnett L; Heller G
    Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
    Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
    Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Giralt S; Hester J; Huh Y; Hirsch-Ginsberg C; Rondón G; Seong D; Lee M; Gajewski J; Van Besien K; Khouri I; Mehra R; Przepiorka D; Körbling M; Talpaz M; Kantarjian H; Fischer H; Deisseroth A; Champlin R
    Blood; 1995 Dec; 86(11):4337-43. PubMed ID: 7492795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.
    Serrano J; Roman J; Sanchez J; Jimenez A; Castillejo JA; Herrera C; Gonzalez MG; Reina L; Rodriguez MC; Alvarez MA; Maldonado J; Torres A
    Blood; 2000 Apr; 95(8):2659-65. PubMed ID: 10753848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation.
    Agaliotis DP; Papenhausen PR; Moscinski LC; Elfenbein GJ
    Ann Hematol; 1995 Jan; 70(1):37-41. PubMed ID: 7827205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
    Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimations of BCR-ABL/ABL transcripts by quantitative PCR in chronic myeloid leukaemia after allogeneic bone marrow transplantation and donor lymphocyte infusion.
    Otazú IB; Tavares Rde C; Hassan R; Zalcberg I; Tabak DG; Seuánez HN
    Leuk Res; 2002 Feb; 26(2):129-41. PubMed ID: 11755463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia.
    Mackinnon S; Barnett L; Heller G; O'Reilly RJ
    Blood; 1994 Jun; 83(11):3409-16. PubMed ID: 8193379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
    Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
    Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT).
    Gaiger A; Lion T; Kalhs P; Mitterbauer G; Henn T; Haas O; Födinger M; Kier P; Forstinger C; Quehenberger P
    Leukemia; 1993 Nov; 7(11):1766-72. PubMed ID: 8231244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.
    Drobyski WR; Keever CA; Roth MS; Koethe S; Hanson G; McFadden P; Gottschall JL; Ash RC; van Tuinen P; Horowitz MM
    Blood; 1993 Oct; 82(8):2310-8. PubMed ID: 8400284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.